News

Moby summary of Tempus AI, Inc.'s Q1 2026 earnings call

Tempus (TEM) delivered earnings and revenue surprises of +38.10% and +0.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Investors are watching Tempus AI (NASDAQ:TEM) ahead of first-quarter results due after the close tomorrow. The stock burst into investor consciousness in January 2025 after Nancy Pelosi disclosed a position, ran past $100, and has since shed nearly half its value. From Pelosi Halo to Show-Me Story Pelosi’s market-beating track record has turned her trades ... Can Nancy Pelosi’s Favorite AI Stock Hope to Regain Its Momentum?

In April 2026, the Keck School of Medicine of USC and Keck Medicine of USC announced a broad collaboration with Tempus AI to embed its genomic testing, AI tools, and data platform across more than 1.5 million annual patient visits in their Southern California network. This partnership not only expands Tempus AI’s clinical footprint but also deepens its access to real-world oncology data, reinforcing the company’s core data-network advantage in precision medicine. With this USC collaboration...

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of -89.47% and +4.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Tempus AI Inc. (NASDAQ:TEM) is one of the best up and coming stocks with highest upside potential. On April 23, Tempus AI and the Keck School of Medicine of USC launched a multi-faceted collaboration aimed at integrating artificial intelligence and data-driven insights into Southern California’s healthcare landscape. This partnership will impact over 1.5 million annual […]

Is TEM a good stock to buy? We came across a bullish thesis on Tempus AI, Inc. on Joe Gannon’s Substack by Gannon Capital. In this article, we will summarize the bulls’ thesis on TEM. Tempus AI, Inc.’s share was trading at $56.78 as of April 20th. TEM’s trailing P/E was 39.30 according to Yahoo Finance. Tempus AI, Inc. operates as […]

TEM and ILMN battle in precision oncology, but stronger stock gains, valuation and earnings outlook position ILMN as the more compelling pick now.

Tempus AI (TEM) has been drawing attention after recent share price moves, with the stock showing a gain over the past month but a decline across the past 3 months and year to date. See our latest analysis for Tempus AI. The recent 10.61% 1 month share price return contrasts with a 16.38% 3 month share price decline and a 19.79% year to date share price loss. Recent momentum therefore appears more like a short term bounce than a sustained trend, even though the 1 year total shareholder return...

The blended fair value estimate for Tempus AI has been adjusted slightly, moving from US$72.73 to US$72.40 as part of the latest round of analyst model updates. This small shift sits against a mixed research backdrop, where some firms are lifting targets after Q4 while others are trimming estimates and highlighting questions around data monetization, partnerships and the balance between growth and visibility. As you read on, you will see how to track these moving pieces and what to watch as...

Tempus AI (NasdaqGS:TEM) was named to TIME’s 10 Most Influential Health and Life Science Companies of 2026. The company expanded its clinical and research reach through a multi year collaboration with the Keck School of Medicine of USC and Keck Medicine of USC. The partnership is aimed at advancing AI driven precision medicine and applying Tempus tools across patient care and research programs. Tempus AI focuses on applying artificial intelligence to precision medicine, with products that...

TruBridge (TBRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TEM faces pressure ahead of Q1 earnings as macro headwinds, high valuation and estimate trends cloud its near-term investment appeal.